Fate Therapeutics Inc (NASDAQ: FATE) established initial surge of 5.93% at $1.25, as the Stock market unbolted on Thursday, before settling in for the price of $1.18 at the close. Taking a more long-term approach, FATE posted a 52-week range of $0.66-$1.94.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -2.63%. Meanwhile, its Annual Earning per share during the time was -2.63%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 29.82%. This publicly-traded company’s shares outstanding now amounts to $115.34 million, simultaneously with a float of $109.23 million. The organization now has a market capitalization sitting at $144.19 million.
Fate Therapeutics Inc (FATE) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Fate Therapeutics Inc industry. Fate Therapeutics Inc’s current insider ownership accounts for 5.30%, in contrast to 71.34% institutional ownership. According to the most recent insider trade that took place on Jan 09 ’26, this organization’s insider sold 10,589 shares at the rate of 1.06, making the entire transaction reach 11,275 in total value, affecting insider ownership by 387,081. Preceding that transaction, on Jan 09 ’26, Company’s President and CEO sold 5,190 for 1.07, making the whole transaction’s value amount to 5,557. This particular insider is now the holder of 329,708 in total.
Fate Therapeutics Inc (FATE) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
Fate Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 29.82% and is forecasted to reach -1.16 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 11.87% through the next 5 years, which can be compared against the -2.63% growth it accomplished over the previous five years trading on the market.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
Let’s observe the current performance indicators for Fate Therapeutics Inc (FATE). It’s Quick Ratio in the last reported quarter now stands at 7.87. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 20.20.
In the same vein, FATE’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.32, a figure that is expected to reach -0.27 in the next quarter, and analysts are predicting that it will be -1.16 at the market close of one year from today.
